{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:02:49Z","timestamp":1784516569336,"version":"3.55.0"},"reference-count":83,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Melanoma is an aggressive skin cancer that has the potential to metastasize to the lymph nodes, lungs, liver, and brain. Therefore, the prevention and treatment of this condition are essential for achieving lower incidence rates and improving patient outcomes. Traditional treatment methods like surgery, radiation therapy, and chemotherapy have shown limited efficacy in the treatment of metastatic melanoma, and hence new treatment strategies have been developed. These recently developed treatment options include combining targeted therapies with immunotherapies to reduce drug resistance and improve overall effectiveness in preventing melanoma progression. Moreover, BRAF mutations are found in approximately 40\u201350% of cutaneous melanomas, and NRAS mutations in 15\u201325%, making these the two most common oncogenic drivers in the MAPK pathway. While alterations in other genes such as KRAS (~1.7%), HRAS (~1%), and MET (~2\u20134%) are relatively rare in melanoma, they still remain important to disease biology and are under investigation as potential therapeutic targets. These alterations may contribute to tumor progression, metastasis, and therapeutic resistance, highlighting the importance of continued investigation of targeted strategies in melanoma. This review aims to explore the role of each of these genes in melanoma, discusses their resistance mechanism, and summarizes preclinical and clinical trials involving drug combinations. By integrating current evidence on melanoma-associated genomic alterations with available targeted and immune approaches, this review aims to define molecular and clinical contexts that suggest potential treatment selections for melanoma patients.<\/jats:p>","DOI":"10.3390\/cancers18142310","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:32:08Z","timestamp":1784514728000},"page":"2310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Molecular-Targeted Therapies in Melanoma and Their Mechanism of Resistance"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0397-7779","authenticated-orcid":false,"given":"Rose","family":"Bahari","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7093-0500","authenticated-orcid":false,"given":"Molly","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyab","family":"Sohail","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2062-0854","authenticated-orcid":false,"given":"Stephanie","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3548-247X","authenticated-orcid":false,"given":"Subaranjana","family":"Saravanaguru Vasanthi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4795-1659","authenticated-orcid":false,"given":"Jeeya","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-2877","authenticated-orcid":false,"given":"Dhruv","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4664-4576","authenticated-orcid":false,"given":"Georgia","family":"Kapetaneas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5871-686X","authenticated-orcid":false,"given":"Riya","family":"Karne","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Altayeh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Joi","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8414-2211","authenticated-orcid":false,"given":"Aneri Prashant","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-5361","authenticated-orcid":false,"given":"Neelu","family":"Puri","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1001\/jama.2025.13074","article-title":"Cutaneous Melanoma: A Review","volume":"334","author":"Joshi","year":"2025","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CMR.0000000000000628","article-title":"Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: A systemic review","volume":"30","author":"Nova","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2017). Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med. Sci., 5.","DOI":"10.3390\/medsci5040028"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1055-9965.EPI-06-1038","article-title":"Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma","volume":"16","author":"Thomas","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","article-title":"Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: The randomized phase 2 NeoTrio trial","volume":"30","author":"Long","year":"2024","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1073\/pnas.1105026109","article-title":"Targeting oncogenic serine\/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia","volume":"109","author":"Bottos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Welti, M., Dimitriou, F., Gutzmer, R., and Dummer, R. (2022). Triple Combination of Immune Checkpoint Inhibitors and BRAF\/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14225489"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","article-title":"Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: Safety and tolerability results from the phase I IMMU-TARGET trial","volume":"158","author":"Zimmer","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2217\/fon-2021-1486","article-title":"STARBOARD: Encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma","volume":"18","author":"Schadendorf","year":"2022","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"LBA9507","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9507","article-title":"A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)","volume":"43","author":"Eroglu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Huynh, S., Mortier, L., Dutriaux, C., Maubec, E., Boileau, M., Dereure, O., Leccia, M.T., Arnault, J.P., Brunet-Possenti, F., and Aubin, F. (2020). Combined Therapy with Anti-PD1 and BRAF and\/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12061666"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","article-title":"Phase Ib\/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma","volume":"28","author":"Schuler","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1200\/JCO.2025.43.16_suppl.9552","article-title":"Nautilus, a phase 1b\/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM)","volume":"43","author":"Amaria","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study","volume":"41","author":"Dooms","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2021.39.15_suppl.3007","article-title":"A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion","volume":"39","author":"Shin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114008","DOI":"10.1016\/j.ejca.2024.114008","article-title":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma","volume":"202","author":"Wei","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1078-0432.CCR-23-3135","article-title":"Phase I\/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors","volume":"30","author":"Corcoran","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rager, T., Eckburg, A., Patel, M., Qiu, R., Gantiwala, S., Dovalovsky, K., Fan, K., Lam, K., Roesler, C., and Rastogi, A. (2022). Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. Cancers, 14.","DOI":"10.3390\/cancers14153779"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1479-5876-10-246","article-title":"Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)","volume":"10","author":"Gajewski","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3892\/ol.2022.13290","article-title":"Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K\/AKT signaling pathways","volume":"23","author":"Jing","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_30","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ra7","DOI":"10.1126\/scisignal.2003057","article-title":"Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells","volume":"6","author":"Beck","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jclinpath-2021-207517","article-title":"Gene of the month: Lymphocyte-activation gene 3 (LAG-3)","volume":"74","author":"Lythgoe","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11864-022-01006-7","article-title":"BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies","volume":"23","author":"Zhong","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ Signaling and Resistance to Cancer Therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI70156","article-title":"WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors","volume":"124","author":"Anastas","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bokharaie, H., Kolch, W., and Krstic, A. (2022). Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells. Biomolecules, 12.","DOI":"10.1101\/2022.03.16.484656"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11912-022-01243-x","article-title":"Triplet Therapy in Melanoma\u2014Combined BRAF\/MEK Inhibitors and Anti-PD-(L)1 Antibodies","volume":"24","author":"Patel","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","article-title":"Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial","volume":"15","author":"Ascierto","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2025.43.16_suppl.9506","article-title":"DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)\u2014Final clinical results","volume":"43","author":"Atkins","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., and Puri, N. (2021). Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13051115"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lai, X., and Friedman, A. (2017). Combination therapy for melanoma with BRAF\/MEK inhibitor and immune checkpoint inhibitor: A mathematical model. BMC Syst. Biol., 11.","DOI":"10.1186\/s12918-017-0446-9"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5414\/CP204184","article-title":"Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF(V600E)-mutated poorly differentiated thyroid cancer: A case report and review of the literature","volume":"60","author":"Zeng","year":"2022","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103090","DOI":"10.1016\/j.ctrv.2026.103090","article-title":"Insights into RAS-driven melanoma and its therapeutic implications","volume":"143","author":"Chatziioannou","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kareff, S.A., Trabolsi, A., Krause, H.B., Samec, T., Elliott, A., Rodriguez, E., Olazagasti, C., Watson, D.C., Bustos, M.A., and Hoon, D.S.B. (2024). The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors. Cancers, 16.","DOI":"10.3390\/cancers16081572"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5356737","DOI":"10.1155\/2017\/5356737","article-title":"The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma","volume":"2017","author":"Wan","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41388-023-02638-1","article-title":"Ras protein abundance correlates with Ras isoform mutation patterns in cancer","volume":"42","author":"Hood","year":"2023","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3892\/ol.2016.4837","article-title":"Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation","volume":"12","author":"Lee","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_56","first-page":"132","article-title":"\u201cUndruggable KRAS\u201d: Druggable after all","volume":"39","author":"Cox","year":"2025","journal-title":"Genes Dev."},{"key":"ref_57","first-page":"3894","article-title":"A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies","volume":"7","author":"Britten","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1158\/1078-0432.CCR-04-1659","article-title":"Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors","volume":"11","author":"Papadimitrakopoulou","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/jid.2010.297","article-title":"The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells","volume":"131","author":"Niessner","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","article-title":"Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma","volume":"4","author":"Burd","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.23.00205","article-title":"Targeting NRAS Mutations in Advanced Melanoma","volume":"41","author":"Phadke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ijc.34807","article-title":"BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms","volume":"154","author":"Dinter","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"TPS3178","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3178","article-title":"An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1)","volume":"42","author":"Spira","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40265-024-02072-x","article-title":"Tunlametinib: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1535-7163.MCT-24-0369","article-title":"Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4\/6 and MEK Inhibition in RASmut Disease Models","volume":"23","author":"Wu","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ijc.31199","article-title":"HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma","volume":"142","author":"Gallagher","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yang, Y., Zhang, H., Huang, S., and Chu, Q. (2023). KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020709"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Vanni, I., Tanda, E.T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., and Ghiorzo, P. (2020). Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00172"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/cbt.29451","article-title":"Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy","volume":"15","author":"Etnyre","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Czyz, M. (2018). HGF\/c-MET Signaling in Melanocytes and Melanoma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123844"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Machiraju, D., and Hassel, J.C. (2022). Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1068029"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/156652411800615153","article-title":"Resistance to chemotherapy and molecularly targeted therapies: Rationale for combination therapy in malignant melanoma","volume":"11","author":"Wu","year":"2011","journal-title":"Curr. Mol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3892\/etm.2023.12115","article-title":"Advances in targeted therapy and immunotherapy for melanoma (Review)","volume":"26","author":"Qin","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Seyhan, A.A., and Carini, C. (2022). Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010041"},{"key":"ref_79","first-page":"e69301","article-title":"A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report","volume":"16","author":"Mihaila","year":"2024","journal-title":"Cureus"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/2159-8290.CD-16-0146","article-title":"Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy","volume":"6","author":"Mandal","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Haist, M., Stege, H., Ebner, R., Fleischer, M.I., Loquai, C., and Grabbe, S. (2022). The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF\/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study. Cancers, 14.","DOI":"10.3390\/cancers14092082"},{"key":"ref_82","first-page":"42","article-title":"Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma","volume":"7","author":"Jalil","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"Ismail","year":"2020","journal-title":"Int. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:47:51Z","timestamp":1784515671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":83,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142310"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142310","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}